Lyell Immunopharma, Inc. — Director's Dealing 2025

Jun 11, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2025-06-09

Reporting Person: Bachleda Mark (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-06-09	Option (right to buy)	$12.47	A	13000	Acquired	2035-06-08	Common Stock (13000)	Direct

Footnotes

F1: 1/36th of the shares of Common Stock subject to the option shall vest on a monthly basis following the grant date on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month), subject to the Reporting Person remaining in service as a director through the applicable vesting date.